A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
- Status
- RECRUITING
- Phase
- PHASE4
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
- Status
- RECRUITING
- Phase
- PHASE1
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
- Status
- RECRUITING
- Phase
- PHASE1
IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma
- Status
- COMPLETED
- Phase
- NA
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
- Status
- RECRUITING
- Phase
- PHASE2
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Status
- RECRUITING
- Phase
- PHASE3
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia
- Status
- RECRUITING
- Phase
- NA
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
- Status
- RECRUITING
- Phase
- PHASE3
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
- Status
- RECRUITING
- Phase
- PHASE1
Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)
- Status
- RECRUITING
- Phase
- N/A